According to Orient's announcement, the company received the “Drug GMP Compliance Inspection Notice” issued by the Zhejiang Drug Administration and inspected its 806, 863, 802 and related production lines at the production site in Tiantai County, Zhejiang Province from November 12 to 14, 2025, involving the active ingredients mometasone furoate and betamethasone, which were concluded to meet the relevant requirements. In 2024, the hospital sales of mometasone furoate preparations and betamethasone preparations were 1.43 billion yuan and 15 million yuan respectively. The results of this inspection will not have a significant impact on performance. Product sales are affected by multiple factors and are uncertain.

According to Orient's announcement, the company received the “Drug GMP Compliance Inspection Notice” issued by the Zhejiang Drug Administration and inspected its 806, 863, 802 and related production lines at the production site in Tiantai County, Zhejiang Province from November 12 to 14, 2025, involving the active ingredients mometasone furoate and betamethasone, which were concluded to meet the relevant requirements. In 2024, the hospital sales of mometasone furoate preparations and betamethasone preparations were 1.43 billion yuan and 15 million yuan respectively. The results of this inspection will not have a significant impact on performance. Product sales are affected by multiple factors and are uncertain.